Full-Time

Regional Vice President of Sales

Sales

Lirio

Lirio

51-200 employees

Behavioral-AI health engagement personalisation engine

Compensation Overview

$180k/yr

+ Variable compensation

No H1B Sponsorship

Tennessee, USA

Remote

Onboarding requires one week onsite in Tennessee.

Category
Sales & Account Management (1)
Required Skills
Sales
Public Speaking
Machine Learning
Salesforce

Get referred to Lirio

See people who can refer or advise you

Requirements
  • 10+ years of relevant sales experience, preferably in earlier-stage virtual/digital health companies or at a health system
  • Proven success at cultivating highly collaborative relationships across key account functions, including Product, Clinical, National Accounts, Network, Legal and more
  • Experience selling AI/ML solutions at an early-stage healthcare technology company.
  • Experience working with both national and regional Health Systems or Payors
  • Experience with complex contract negotiations
  • Comfortability working independently
  • Superb project management, organizational, communication, meeting prep, and follow-up skills
  • Strong public speaking skills and a willingness to present in front of large audiences when needed
  • Ability to effectively manage multiple priorities in a fast-paced environment
  • A firm understanding and fluency in healthcare economics and trends, specifically across enterprise health systems and health plans
  • Fluency in relationship-building, particularly with key decision-makers
  • Ability to flex between virtual and in-person sales calls when necessary
  • Prior experience with ZoomInfo/Definitive HC & Salesforce.com preferred
Responsibilities
  • Drive new sales with target Health System accounts by developing strategies that drive top of funnel activity and efficiently moving prospects through each stage of the sales funnel to close
  • Understand the network synergy between payers, health systems, employers, consultants, and other influencers and harnesses that influence to create leverage in driving deals forward
  • Work cross-functionally internally to identify and solve gaps that will help move deals forward faster
  • Generate interest in Lirio by building relationships with C-Level executives in target accounts
  • Update and maintain sales pipeline in company CRM (Salesforce)
  • Responsible for earning a “trusted advisor” relationship with prospective clients by focusing on key issues and strategic initiatives, keeping Lirio relevant in the eyes of the executive team

Lirio uses behavioral science and AI to improve patient engagement and health outcomes. Its Precision Nudging personalisation engine analyzes individual behaviors, communication patterns, and social/clinical context to deliver hyper-personalized messages and interventions that encourage adherence and screenings. By moving beyond demographics, it enables real-time, one-to-one outreach to sustain engagement across care journeys, partnering with health systems, payers, and provider organizations. The goal is to reduce gaps in care and lower total cost of care by guiding patients through their evolving healthcare journey.

Company Size

51-200

Company Stage

N/A

Total Funding

$33.1M

Headquarters

Knoxville, Tennessee

Founded

2017

Get referred to Lirio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • October 2025 Precision Nudging for Life Sciences opened a larger pharma market.
  • Cone Health plans five Lirio interventions, showing repeatable enterprise adoption.
  • 2024 Nashville expansion and leadership hires signaled operational scaling beyond Knoxville.

What critics are saying

  • Lirio still lacks visible scaled revenue, despite 2026 seed filings and product launches.
  • Life-sciences messaging faces crowded competition from Salesforce, Veeva, and patient-support vendors.
  • If pharma pilots stall, Lirio's niche platform becomes a services-heavy science project.

What makes Lirio unique

  • Precision Nudging pairs behavioral science with agentic AI and omnichannel activation.
  • Lirio expanded from health systems into life sciences in October 2025.
  • Bon Secours Mercy Health remains a strategic anchor and board-level investor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

10 paid holidays + holiday week company closure

Unlimited Paid Time Off

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
Business Wire
Feb 5th, 2026
Life sciences firms struggle with patient engagement as 70% cite adherence challenges costing $100B annually

Lirio, a behavioural science and AI platform, has released research revealing that traditional personalisation approaches in life sciences fail to improve patient engagement. The survey of over 75 life sciences executives, conducted by Sage Growth Partners, found that more than 70% identified clinical trial engagement and medication adherence as persistent challenges. The report highlights that nearly 50% of patients don't take medications as prescribed, contributing to $100 billion in annual preventable healthcare costs and 125,000 avoidable deaths. Despite growing direct-to-consumer strategies, only half of organisations use digital health technologies for patient engagement, and fewer than 3% partner with specialised vendors. The findings come as new regulations reshape pharmaceutical advertising, prompting life sciences companies to rethink patient engagement strategies beyond traditional mass messaging approaches.

Teknovation.biz
May 5th, 2025
Lirio Releases Report Titled (Re)Defining Personalization

Lirio, the Knoxville-based pioneer in the union of behavioral science and artificial intelligence to deliver better health outcomes, has released new industry findings on the significant impact that advanced health... The post Lirio releases report titled (Re)defining Personalization appeared first on Teknovation.biz.

U.S. Securities and Exchange Commission
May 2nd, 2025
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

U.S. Securities and Exchange Commission
May 2nd, 2025
SEC FORM D/A

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Silverwood Partners
Feb 8th, 2024
Healthcare Private Placement and M&A Transactions Review Week Ending Feb 4, 2024 | Silverwood Partners

Strategy | Financing Transactions Private Placement / Financing Transactions Cellanome: The company raised $150 million of Series B venture funding from Premji Invest (US) and undisclosed investors on January 29, 2024, putting the company’s pre-money valuation at $375 million. The company is a developer of a unique multi-omics platform designed to measure biology at an unprecedented […]